{"transactions":[{"id":851806,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":61834,"kind":"person","name":"Garner Thomas","position":1,"cik":"0001996325","reported_name":"Garner Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2026-03-10T22:00:13.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":28493,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning March 6, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in four equal annual installments beginning March 6, 2027."}],"balance_after":28493,"derivative":{"underlying":"Common Stock","underlying_shares":28493},"source":{"system":"sec-edgar","filing":"0001996325-26-000002","document":"form4-03102026_060309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000199632526000002/form4-03102026_060309.xml","form_type":"4"}},{"id":851805,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":61834,"kind":"person","name":"Garner Thomas","position":1,"cik":"0001996325","reported_name":"Garner Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-10T22:00:13.000Z","date":"2026-03-06","kind":"grant","planned":false,"acquired":true,"shares":97947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option will vest and become exercisable on March 6, 2027. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":97947,"derivative":{"exercise_price":22.16,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":97947},"source":{"system":"sec-edgar","filing":"0001996325-26-000002","document":"form4-03102026_060309.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000199632526000002/form4-03102026_060309.xml","form_type":"4"}},{"id":1337721,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":61834,"kind":"person","name":"Garner Thomas","position":1,"cik":"0001996325","reported_name":"Garner Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-12-10T23:33:31.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":45372,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit granted under the Plan represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"50% of the restricted stock units vest on December 9, 2026 and 25% vest on each of December 9, 2027 and December 9, 2028."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"50% of the restricted stock units vest on December 9, 2026 and 25% vest on each of December 9, 2027 and December 9, 2028."}],"balance_after":45372,"derivative":{"underlying":"Common Stock","underlying_shares":45372},"source":{"system":"sec-edgar","filing":"0001415889-24-028884","document":"form4-12102024_111227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588924028884/form4-12102024_111227.xml","form_type":"4"}},{"id":1337720,"issuer":{"id":3913,"kind":"organization","name":"ACADIA PHARMACEUTICALS INC"},"owners":[{"id":61834,"kind":"person","name":"Garner Thomas","position":1,"cik":"0001996325","reported_name":"Garner Thomas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-10T23:33:31.000Z","date":"2024-12-09","kind":"grant","planned":false,"acquired":true,"shares":235849,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the Stock Option granted under the 2024 Equity Incentive Plan (the \"Plan\") will vest and become exercisable on December 9, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter."}],"balance_after":235849,"derivative":{"exercise_price":18.76,"expiration_date":"2034-12-08","underlying":"Common Stock","underlying_shares":235849},"source":{"system":"sec-edgar","filing":"0001415889-24-028884","document":"form4-12102024_111227.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070494/000141588924028884/form4-12102024_111227.xml","form_type":"4"}},{"id":1649932,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":61834,"kind":"person","name":"Garner Thomas","position":1,"cik":"0001996325","reported_name":"Garner Thomas","relationship":{"officer":true,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-12T21:14:04.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":227130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter."}],"balance_after":227130,"derivative":{"exercise_price":2.15,"expiration_date":"2034-02-08","underlying":"Common Stock","underlying_shares":227130},"source":{"system":"sec-edgar","filing":"0001127602-24-004460","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224004460/form4.xml","form_type":"4"}},{"id":1649931,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":61834,"kind":"person","name":"Garner Thomas","position":1,"cik":"0001996325","reported_name":"Garner Thomas","relationship":{"officer":true,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-12T21:14:04.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":227130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant."}],"balance_after":227130,"derivative":{"underlying":"Common Stock","underlying_shares":227130},"source":{"system":"sec-edgar","filing":"0001127602-24-004460","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760224004460/form4.xml","form_type":"4"}},{"id":1761985,"issuer":{"id":4970,"kind":"organization","name":"LEXICON PHARMACEUTICALS, INC."},"owners":[{"id":61834,"kind":"person","name":"Garner Thomas","position":1,"cik":"0001996325","reported_name":"Garner Thomas","relationship":{"officer":true,"officer_title":"SVP, Chief Commercial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-10-11T20:02:24.000Z","date":"2023-10-09","kind":"grant","planned":false,"acquired":true,"shares":248923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (10/9/2024) and vests 1/48th per month for each month of service thereafter."}],"balance_after":248923,"derivative":{"exercise_price":1.08,"expiration_date":"2033-10-09","underlying":"Common Stock","underlying_shares":248923},"source":{"system":"sec-edgar","filing":"0001127602-23-025765","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1062822/000112760223025765/form4.xml","form_type":"4"}}]}